ARTICLE | Company News
NICE recommends Darzalex to treat MM, almost two years after European approval
March 21, 2019 11:46 PM UTC
The U.K.'s NICE recommended this month that Janssen Biotech's Darzalex daratumumab be available through the Cancer Drugs Fund as a second-line treatment for relapsed multiple myeloma in combination with bortezomib plus dexamethasone. The European Commission granted the drug full approval for the indication in April 2017.
Darzalex, a human IgG1k mAb against CD38, is approved in several settings to treat MM, as monotherapy and in combinations...
BCIQ Target Profiles